$VRAX

Virax Biolabs Group Ltd

CIK:0001885827|SEC Filings

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Mar. 31, 2024
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	$ 12,423	$ 6,331	$ 156,419
Cost of revenue	4,733	59,398	105,829
Gross profit (loss)	7,690	(53,067)	50,590
Operating expenses:
General and administrative	2,669,062	3,992,400	4,571,279
Research & development	3,738,358	2,031,335	1,614,636
Impairment of intangible asset	0	0	390,355
Total operating expenses	6,407,420	6,023,735	6,576,270
Operating loss	(6,399,730)	(6,076,802)	(6,525,680)
Other income (expense):
Interest expense, net	(61,772)	(58,179)	(26,878)
Other income (expense), net	33	17,183	(215,769)
Foreign currency gain (loss), net	529,045	(86,095)	29,207
Total other income (expense), net	467,306	(127,091)	(213,440)
Loss before income taxes	(5,932,424)	(6,203,893)	(6,739,120)
Income tax benefit	(900,240)	(136,661)	(0)
Net loss	(5,032,184)	(6,067,232)	(6,739,120)
Net loss attributable to non-controlling interest	(8,434)	(5,985)	(5,583)
Net loss attributable to Virax Biolabs shareholders	(5,023,750)	(6,061,247)	(6,733,537)
Other comprehensive income (loss):
Foreign currency adjustment	422,608	(110,379)	(3,639)
Total Comprehensive loss	(5,454,792)	(5,956,853)	(6,735,481)
Comprehensive loss attributable to non-controlling interest	(8,434)	(5,985)	(5,583)
Comprehensive loss attributable to Virax Biolabs shareholders	$ (5,446,358)	$ (5,950,868)	$ (6,729,898)
Basic and diluted weighted average shares outstanding
Ordinary shares	397,590	149,214	80,257
Diluted ordinary shares	397,590	149,214	80,257
Basic and diluted net loss per share to Virax Biolabs shareholders*
Basic net loss per share - Ordinary shares	$ (12.64)	$ (40.62)	$ (83.9)
Diluted net loss per share - Ordinary shares	$ (12.64)	$ (40.62)	$ (83.9)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2026	Mar. 31, 2025	Mar. 31, 2024
Cash flows from operating activities:
Net Loss	$ (5,032,184)	$ (6,067,232)	$ (6,739,120)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	361,229	266,601	54,870
Amortization of right-of-use assets	77,789	76,786	48,229
Impairment of intangible asset			390,355
Accretion expense	51,875	45,600	30,003
Stock-based compensation	130,409	365,309	1,011,973
Loss on disposal of property, plant & equipment	32,187
Gain on debt extinguishment			(12,465)
Other expense			85,500
Foreign currency translation (gain) loss	(501,927)	123,743	3,668
Net changes in operating assets & liabilities:
Prepaid expenses and deposits	176,805	(26,600)	(231,307)
VAT receivable	3,542	187,189	(217,843)
Inventories	94,675	(34,292)	(60,383)
Loan payable	(3,991)	32,468	(149,906)
Accounts payable - related parties	(71,594)	337,576
Deferred revenue			(38,250)
Accounts payable and accrued liabilities	59,293	129,276	(572,246)
Net cash used in operating activities	(4,621,892)	(4,563,576)	(6,396,922)
Cash flows from investing activities:
Investment - internally developed software			(211,952)
Purchase of property, plant & equipment	(255,831)	(603,890)	(952,497)
Net cash used in investing activities	(255,831)	(603,890)	(1,164,449)
Cash flows from financing activities:
Lease payments	(109,482)	(107,756)	(56,366)
Payments to related parties			(18,296)
Proceeds from shares issuance for cash	2,782,707	5,128,186	234
Proceeds from PIPE transaction	4,413,758
Proceeds from warrant exercise	705	786,736	1,872,505
Net cash provided by financing activities	7,087,688	5,807,166	1,798,077
Net change in cash	2,209,965	639,700	(5,763,294)
Cash at beginning of year	4,228,944	3,589,244	9,352,538
Cash at end of year	6,438,909	4,228,944	3,589,244
Supplemental disclosure of cash flow information
Interest	40,998	(78,953)	6,104
Supplemental disclosure of non-cash investing and financing activities:
Addition of Right-of-use assets	$ 80,862	$ 181,641	$ 254,319

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)	Mar. 31, 2026	Mar. 31, 2025
Current assets:
Cash	$ 6,438,909	$ 4,228,944
VAT receivable	27,112	30,654
Inventories	0	94,675
Prepaid expenses and deposits	362,577	539,382
Total current assets	6,828,598	4,893,655
Non-current assets
Right-of-use assets, net	327,381	306,652
Property, plant & equipment, net	1,168,793	1,226,596
Total non-current assets	1,496,174	1,533,248
Total assets	8,324,772	6,426,903
Current liabilities:
Accounts payable and accrued liabilities	309,463	250,170
Lease liabilities, current	81,102	52,993
Accounts payable - related parties	265,982	337,576
Loan payable	28,477	32,468
Total current liabilities	685,024	673,207
Non-current liabilities:
Non-current lease liabilities	304,808	291,543
Total liabilities	989,832	964,750
Commitment and contingencies (Note 15)
Virax Biolabs Shareholders' equity
Ordinary shares, $0.01 par value, 2,000,000 shares authorized; 579,218 and 173,679 issued and outstanding as of March 31, 2026 and 2025, respectively	14,480	4,342
Reserves	37,486,133	30,168,692
Accumulated deficit	(29,612,994)	(24,589,244)
Accumulated Other Comprehensive Income (loss)	(310,278)	112,330
Total shareholders' equity (Virax Biolabs)	7,577,341	5,696,120
Non-controlling interests	(242,401)	(233,967)
Total shareholders' equity attributable to Virax Biolabs ordinary shareholders	7,334,940	5,462,153
Total liabilities and shareholders' equity	$ 8,324,772	$ 6,426,903